PE20070613A1 - Nueva asociacion entre agomelatina y un agente timoregulador y composiciones farmaceuticas que la contienen - Google Patents

Nueva asociacion entre agomelatina y un agente timoregulador y composiciones farmaceuticas que la contienen

Info

Publication number
PE20070613A1
PE20070613A1 PE2006001069A PE2006001069A PE20070613A1 PE 20070613 A1 PE20070613 A1 PE 20070613A1 PE 2006001069 A PE2006001069 A PE 2006001069A PE 2006001069 A PE2006001069 A PE 2006001069A PE 20070613 A1 PE20070613 A1 PE 20070613A1
Authority
PE
Peru
Prior art keywords
agent
timoregulator
agomelatin
pharmaceutical compositions
compositions containing
Prior art date
Application number
PE2006001069A
Other languages
English (en)
Inventor
Bodinat Christian De
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36190792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20070613A1 publication Critical patent/PE20070613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AGLOMETINA (N-[2-(7-METOXI-1-NAFTIL)ETIL]ACETAMIDA) Y UN AGENTE TIMO-REGULADOR TAL COMO VALPROATO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DEL HUMOR Y, PARTICULARMENTE TRASTORNO DEPRESIVO MAYOR, DEL TRASTORNO CICLOTIMICO Y DEL TRASTORNO DISTIMICO
PE2006001069A 2005-09-09 2006-09-04 Nueva asociacion entre agomelatina y un agente timoregulador y composiciones farmaceuticas que la contienen PE20070613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509208A FR2890563B1 (fr) 2005-09-09 2005-09-09 Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20070613A1 true PE20070613A1 (es) 2007-07-30

Family

ID=36190792

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001069A PE20070613A1 (es) 2005-09-09 2006-09-04 Nueva asociacion entre agomelatina y un agente timoregulador y composiciones farmaceuticas que la contienen

Country Status (38)

Country Link
US (1) US7902180B2 (es)
EP (2) EP1762238B1 (es)
JP (1) JP2007077149A (es)
KR (2) KR20070029607A (es)
CN (1) CN1927194A (es)
AP (1) AP3045A (es)
AR (1) AR055418A1 (es)
AT (1) ATE519482T1 (es)
AU (1) AU2006209371B2 (es)
BR (1) BRPI0603767A (es)
CA (1) CA2558764C (es)
CY (1) CY1112223T1 (es)
DK (1) DK1762238T3 (es)
EA (1) EA014381B1 (es)
ES (1) ES2371482T3 (es)
FR (1) FR2890563B1 (es)
GE (1) GEP20094741B (es)
GT (1) GT200600410A (es)
HR (1) HRP20110749T1 (es)
JO (1) JO2746B1 (es)
MA (1) MA28504B1 (es)
ME (1) ME01964B (es)
MX (1) MXPA06010234A (es)
MY (1) MY162318A (es)
NO (1) NO338079B1 (es)
NZ (1) NZ549727A (es)
PE (1) PE20070613A1 (es)
PL (1) PL1762238T3 (es)
PT (1) PT1762238E (es)
RS (1) RS52003B (es)
SA (1) SA110320045B1 (es)
SG (1) SG131029A1 (es)
SI (1) SI1762238T1 (es)
TW (1) TWI369980B (es)
UA (1) UA83541C2 (es)
UY (1) UY29776A1 (es)
WO (1) WO2007028903A1 (es)
ZA (1) ZA200607532B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU4748100A (en) * 1999-04-29 2000-11-17 Merck Patent Gmbh Glycine cleavage system inhibitors as potential antipsychotics
JP4249415B2 (ja) * 1999-12-01 2009-04-02 ユセベ，ソシエテ アノニム Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Also Published As

Publication number Publication date
AP3045A (en) 2014-11-30
NO338079B1 (no) 2016-07-25
RS52003B (en) 2012-04-30
UA83541C2 (uk) 2008-07-25
US20070066689A1 (en) 2007-03-22
AU2006209371B2 (en) 2012-02-02
TW200800860A (en) 2008-01-01
SA110320045B1 (ar) 2014-01-29
HRP20110749T1 (hr) 2011-11-30
SG131029A1 (en) 2007-04-26
ME01964B (me) 2012-04-30
NO20064049L (no) 2007-03-12
ES2371482T3 (es) 2012-01-03
UY29776A1 (es) 2006-11-30
GEP20094741B (en) 2009-07-27
FR2890563A1 (fr) 2007-03-16
ZA200607532B (en) 2008-05-28
GT200600410A (es) 2007-05-21
CN1927194A (zh) 2007-03-14
JO2746B1 (en) 2014-03-15
MXPA06010234A (es) 2007-03-08
PT1762238E (pt) 2011-09-01
CY1112223T1 (el) 2015-12-09
KR20090056949A (ko) 2009-06-03
FR2890563B1 (fr) 2007-10-19
EP1762238A1 (fr) 2007-03-14
ATE519482T1 (de) 2011-08-15
JP2007077149A (ja) 2007-03-29
MA28504B1 (fr) 2007-04-03
EP1762238B1 (fr) 2011-08-10
CA2558764C (fr) 2013-01-08
KR20070029607A (ko) 2007-03-14
EA200601450A1 (ru) 2007-04-27
TWI369980B (en) 2012-08-11
AU2006209371A1 (en) 2007-03-29
MY162318A (en) 2017-05-31
EA014381B1 (ru) 2010-10-29
DK1762238T3 (da) 2011-11-07
WO2007028903A1 (fr) 2007-03-15
NZ549727A (en) 2008-03-28
US7902180B2 (en) 2011-03-08
AR055418A1 (es) 2007-08-22
CA2558764A1 (fr) 2007-03-09
BRPI0603767A (pt) 2007-08-14
AP2008004380A0 (en) 2008-04-30
PL1762238T3 (pl) 2011-12-30
SI1762238T1 (sl) 2011-10-28
EP2301527A1 (fr) 2011-03-30

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
CL2008000893A1 (es) Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal.
PE20142372A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
AR072515A1 (es) Composiciones y metodos para el blanqueamiento dental
JOP20150301B1 (ar) بنزاميدات مستبدلة مع 3،1-ثيازول-2- يل
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2012000793A1 (es) Composicion farmaceutica que comprende 1-cloro-4-(3-d-glucopiranos-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]benceno, clorhidrato de metformina y uno o mas excipientes farmaceuticos.
DOP2011000188A (es) Compuestos de tiazolopiridinas moduladores de sirtuina
PE20191557A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1
CR10684A (es) Metodos para administrar agentes hipoglicemicos de larga duracion
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
UY31780A (es) Fenoxibenzamidas sustituidas
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
PE20150709A1 (es) Benzamidas
CL2012002815A1 (es) Composicion para el cuidado bucal que comprende uno o mas compuesto de curcumina y una fuente de iones de zinc; correspondiente a 0.02 a 3% en peso de citrato de zinc; y uso de una fuente de iones de zinc para suprimir la degradacion y/o decoloracion del compuesto de curcumina en una composicion ara el cuidado bucal.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
AR075063A1 (es) Composiciones que comprenden agentes tensoactivos no ionicos y zwiterionicos
AR056558A1 (es) Metodos para estabilizar composiciones oftalmicas
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.

Legal Events

Date Code Title Description
FC Refusal